Income Taxes (Tables)
|
12 Months Ended |
May 31, 2025 |
Dec. 31, 2024 |
Income Taxes [Line Items] |
|
|
Schedule of Provision for Income Taxes Expenses |
|
The components of the provision for Income taxes expenses are:
|
|
Year ended December 31, 2024
|
|
Year ended December 31, 2023
|
|
Year ended December 31, 2022
|
Current
|
|
$
|
—
|
|
$
|
—
|
|
$
|
—
|
Deferred
|
|
|
—
|
|
|
—
|
|
|
—
|
Total income taxes expense
|
|
$
|
—
|
|
$
|
—
|
|
|
—
|
|
Schedule of Income Taxes Expenses Computed at the Hong Kong Statutory Tax Rate |
|
The reconciliation of income taxes expenses computed at the Hong Kong statutory tax rate applicable to income tax expense is as follows:
|
|
Year ended December 31, 2024
|
|
Year ended December 31, 2023
|
|
Year ended December 31, 2022
|
Net loss before tax
|
|
$
|
(4,157,737 |
)
|
|
$
|
(4,340,975 |
)
|
|
$
|
(11,525,102 |
)
|
Provision for income tax benefit at Hong Kong statutory income tax rate (16.5%) |
|
|
(686,027 |
) |
|
|
(716,261 |
) |
|
|
(1,901,642 |
) |
Impact of different tax rates in other jurisdictions
|
|
|
(10,814 |
)
|
|
|
(16,272 |
)
|
|
|
(263,787 |
)
|
Non-taxable income
|
|
|
(5,477 |
)
|
|
|
(1,071,774 |
)
|
|
|
(907,495 |
)
|
Non-deductible expenses
|
|
|
195 |
|
|
|
98,704 |
|
|
|
—
|
|
Change in valuation allowance
|
|
|
702,123 |
|
|
|
1,705,603 |
|
|
|
3,072,924 |
|
Effective income tax expense
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
Schedule of Deferred Tax Asset and Liabilities |
|
The following represents the tax effect of each major type of temporary difference.
|
|
December 31, 2024
|
|
December 31, 2023
|
Deferred tax asset:
|
|
|
|
|
|
|
|
|
Tax loss carry forward
|
|
$
|
15,107,318 |
|
|
$
|
16,956,748 |
|
Share-based payment expenses
|
|
|
—
|
|
|
|
229,126 |
|
Depreciation and amortization
|
|
|
128,896 |
|
|
|
128,866 |
|
Impairment loss on assets
|
|
|
537,830 |
|
|
|
92,416 |
|
Total Deferred tax asset
|
|
|
15,774,044 |
|
|
|
17,407,156 |
|
Valuation allowance
|
|
|
(15,774,044 |
)
|
|
|
(17,407,156 |
)
|
Deferred tax asset, net of valuation allowance
|
|
$
|
—
|
|
|
$
|
—
|
|
|
Schedule of Changes in Valuation Allowance |
|
Changes in valuation allowance are as follows:
|
|
Year ended December 31, 2024
|
|
Year ended December 31, 2023
|
|
Year ended December 31, 2022
|
Balance as of January 1
|
|
$
|
17,407,156 |
|
|
$
|
15,705,088 |
|
|
$
|
12,632,164 |
Additions
|
|
|
702,123 |
|
|
|
1,705,603 |
|
|
|
3,072,924 |
Disposal
|
|
|
(2,335,235 |
)
|
|
|
(3,535 |
)
|
|
|
—
|
Balance as of December 31
|
|
$
|
15,774,044 |
|
|
$
|
17,407,156 |
|
|
$
|
15,705,088 |
|
DiamiR Biosciences Corp. [Member] |
|
|
Income Taxes [Line Items] |
|
|
Schedule of Provision for Income Taxes Expenses |
For the years ended May 31, 2025 and 2024, the provision for income taxes consisted of the following:
|
|
2025
|
|
2024
|
Current:
|
|
|
|
|
|
|
Federal
|
|
$
|
16,483 |
|
$
|
112,947 |
State
|
|
|
1,456 |
|
|
1,456 |
Total current
|
|
|
17,939 |
|
|
114,403 |
Deferred:
|
|
|
|
|
|
|
Federal
|
|
|
—
|
|
|
—
|
State
|
|
|
—
|
|
|
—
|
Total deferred
|
|
|
—
|
|
|
—
|
Total
|
|
$
|
17,939 |
|
$
|
114,403 |
|
|
Schedule of Income Taxes Expenses Computed at the Hong Kong Statutory Tax Rate |
For the years ended May 31, 2025 and 2024, a reconciliation of the Company’s effective tax rate to the statutory U.S. Federal rate is as follows:
|
|
2025
|
|
2024
|
Income taxes at Federal statutory rate
|
|
21.0 |
%
|
|
21.0 |
%
|
Discounts and interest on notes
|
|
(2.4 |
)%
|
|
(2.1 |
)%
|
Financing costs
|
|
(4.3 |
)%
|
|
—
|
%
|
State taxes
|
|
—
|
%
|
|
(4.2 |
)%
|
Other
|
|
(2.3 |
)%
|
|
(1.2 |
)%
|
Change in valuation allowance
|
|
(14.3 |
)%
|
|
(36.3 |
)%
|
Income tax provision
|
|
(2.3 |
)%
|
|
(22.9 |
)%
|
|
|
Schedule of Deferred Tax Asset and Liabilities |
The Company’s deferred tax assets and liabilities consist of the following at May 31, 2025 and 2024:
|
|
May 31, 2025
|
|
May 31, 2024
|
Deferred tax assets:
|
|
|
|
|
|
|
|
|
Tax benefit of net operating loss carry-forward (NOL)
|
|
$
|
351,453 |
|
|
$
|
247,637 |
|
FIN48 reduction in NOL
|
|
|
(269,420 |
)
|
|
|
(219,793 |
)
|
Stock compensation
|
|
|
351,136 |
|
|
|
346,030 |
|
Research and development expenses
|
|
|
422,170 |
|
|
|
372,544 |
|
Other
|
|
|
1,152 |
|
|
|
2,432 |
|
Total deferred tax assets:
|
|
|
856,490 |
|
|
|
748,850 |
|
Deferred tax liabilities
|
|
|
(8,152 |
)
|
|
|
(4,583 |
)
|
Net deferred tax assets:
|
|
|
848,338 |
|
|
|
744,267 |
|
Valuation allowance for deferred tax assets
|
|
|
(848,338 |
)
|
|
|
(744,267 |
)
|
Deferred tax assets, net of valuation allowance
|
|
$
|
—
|
|
|
$
|
—
|
|
|
|
Schedule of Unrecognized Tax Benefits |
The Company recognizes a tax benefit from an uncertain tax position when it is more-likely-than-not that it will be sustained upon examination by tax authorities.
Unrecognized tax benefits, May 31, 2023
|
|
$
|
217,239 |
Gross increases – tax positions in current period
|
|
|
155,305 |
Unrecognized tax benefits, May 31, 2024
|
|
|
372,544 |
Gross increases – tax positions in current period
|
|
|
49,626 |
Unrecognized tax benefits, May 31, 2025
|
|
$
|
422,170 |
|
|